Public and investor relations for the innovators in healthcare and technology

We’ve been delivering measurable PR and IR results for innovative companies in health and technology since our founding more than 30 years ago originally as Noonan/Russo Communications.  When it comes to raising awareness of your company and product as well as forging new relationships, no one connects you to the people you want to know like we do. Our team of PhD-level scientists, former journalists, TV producers, and Wall Street professionals is on a first-name basis with the who’s who in media, finance, medicine and technology.

United Neuroscience’s ‘endobody’ Parkinson’s vaccine shows promise in early tests

FierceBiotech: Nov 14, 2018 11:27am — United Neuroscience is developing a novel class of vaccines that target aberrant proteins implicated in neurodegenerative diseases. Now it has strong preclinical evidence showing that one of its vaccines could hold promise in Parkinson’s disease.

read more
How Corbus Uses Synthetic Cannabinoids to Fight Diseases

Bloomberg Markets: The Close, November 12th, 2018, 4:12 PM EST — Yuval Cohen, Corbus Pharmaceuticals chief executive officer, discusses how the company is combating autoimmune diseases with Bloomberg’s Ed Hammond on “Bloomberg Markets: The Close.” (Source: Bloomberg)

read more
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity

SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) — Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that the first patient has been enrolled in its “VIVA” (Veinplicity for Improved Venous Access) Trial in the United States for the Veinplicity® Device.

read more